Capital World Investors Sells 322,867 Shares of Humana Inc. (NYSE:HUM)

Capital World Investors lessened its stake in Humana Inc. (NYSE:HUM - Free Report) by 18.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,406,156 shares of the insurance provider's stock after selling 322,867 shares during the period. Capital World Investors owned 1.17% of Humana worth $356,756,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in HUM. FPC Investment Advisory Inc. bought a new stake in shares of Humana in the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC purchased a new position in Humana during the 4th quarter valued at about $30,000. LFA Lugano Financial Advisors SA lifted its position in Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after buying an additional 45 shares in the last quarter. OFI Invest Asset Management acquired a new stake in Humana during the fourth quarter valued at $33,000. Finally, Atwood & Palmer Inc. grew its stake in shares of Humana by 64.5% in the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock valued at $39,000 after buying an additional 60 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Price Performance

Shares of NYSE:HUM traded down $3.91 during midday trading on Friday, reaching $263.92. The company's stock had a trading volume of 1,097,942 shares, compared to its average volume of 1,745,084. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The company has a market capitalization of $31.85 billion, a P/E ratio of 26.52, a P/E/G ratio of 2.05 and a beta of 0.62. The business's fifty day simple moving average is $266.35 and its 200-day simple moving average is $270.50. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, equities research analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.34%. Humana's dividend payout ratio is 35.58%.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Piper Sandler boosted their price target on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a research report on Wednesday, January 15th. Morgan Stanley lowered their target price on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 12th. Barclays upped their price target on Humana from $270.00 to $322.00 and gave the stock an "equal weight" rating in a report on Friday, April 11th. Robert W. Baird raised their price target on shares of Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a research report on Tuesday, April 15th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and set a $290.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Seventeen research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, Humana presently has an average rating of "Hold" and an average target price of $284.90.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.